Similar results were shown for tumor location (GEJ vs. gastric, 10.0 vs. 7.4 months, HR 0.590, 95% CI 0.174–1.995, p = 0.396), HER2 status (IHC3+ vs. IHC2+ and FISH+, 9.1 vs. 7.4 months, HR 0.697, 95% CI 0.222–2.194, p = 0.538), and PD‐L1 expression (CPS ≥1 vs. CPS <1, 10.0 vs. 7.5 months, HR 0.823, 95% CI 0.322–2.102, p = 0.684) (Figure 4). This evidence concerns the gene ERBB2 and neoplasm.